Crizotinib metabolite hydrochloride 13C5, 15N

[13C5, 15N]-Crizotinib metabolite hydrochloride is a compound that is used in the pharmaceutical industry for the treatment of non-small cell lung cancer. It is a metabolite of crizotinib, a medication that is used to treat patients with ALK-positive non-small cell lung cancer. The compound is a hydrochloride salt, which means that it is highly soluble in water and can be readily dissolved in a variety of solvents. The chemical formula of [13C5, 15N]-Crizotinib metabolite hydrochloride is C21H22ClN7O2, and it has a molecular weight of 443.91 g/mol. This compound contains 13 carbon atoms and 5 nitrogen atoms that are labeled with stable isotopes, which makes it useful for pharmacokinetic studies. The labeling allows researchers to track the metabolism of crizotinib and its metabolites in vivo using mass spectrometry. The usage of [13C5, 15N]-Crizotinib metabolite hydrochloride in pharmacokinetic studies is critical for developing new therapies for non-small cell lung cancer. By understanding how the body metabolizes crizotinib and its metabolites, researchers can optimize the dosing regimen of crizotinib to maximize efficacy and minimize toxicity. This compound is also useful for studying drug interactions and identifying potential drug-drug interactions that may affect the efficacy of crizotinib.